Search Results

February 10, 2020

Janssen Announces Submission to U.S. FDA for New DARZALEX® (Daratumumab)-Based Combination Regimen for Patients with Relapsed/Refractory Multiple Myeloma

· Application is based on positive data from the Phase 3 CANDOR study, which were presented at the 2019 American Society of Hematology Annual Meeting

Innovative Medicine

February 3, 2020

Janssen to Highlight Depth of Solid Tumor Portfolio at ASCO GU

New data featured in multiple presentations across prostate and bladder cancer treatment portfolio and pipeline including ERLEADA® (apalutamide), niraparib and BALVERSATM (erdafitinib)

Global health equity

January 16, 2020

Johnson & Johnson Collaborates with The MTV Staying Alive Foundation to Launch Youth-Focused “Edutainment” Campaign Focused on Tuberculosis & Other Health Issues in India

Program aims to raise awareness and reduce stigma of TB among young people in India, as part of Johnson & Johnson’s 10-year initiative to combat world’s leading infectious disease killer

Innovative Medicine

January 15, 2020

Janssen Seeks Expanded Use of SPRAVATO®▼ (Esketamine) Nasal Spray in Europe as a Treatment for Depressive Symptoms in Adults with Major Depressive Disorder Who Have Current Suicidal Ideation with Intent

In two pivotal Phase 3 trials, SPRAVATO®▼ combined with comprehensive standard of care achieved statistically significant rapid reduction of depressive symptoms in patients with major depressive disorder who have current suicidal ideation with intent compared to comprehensive standard of care alone

Corporate

January 6, 2020

Dr. Paul Janssen Award for Biomedical Research Issues 2020 Call for Nominations to Celebrate Champions of Science

Innovative Medicine

December 10, 2019

DARZALEX® (Daratumumab) Regimen Shows Significant Increase in Progression-Free Survival in Treatment of Patients with Relapsed/Refractory Multiple Myeloma

· First Phase 3 study showing addition of the CD38-directed antibody DARZALEX® to carfilzomib in combination with dexamethasone · Data selected as a Late-Breaking Abstract at ASH 2019

Innovative Medicine

December 9, 2019

Janssen to Acquire Investigational Bermekimab from XBiotech

Clinical Stage, First-in-Class Anti-IL-1a Antibody for Atopic Dermatitis and Hidradenitis Suppurativa

Innovative Medicine

December 9, 2019

Janssen Announces BCMA CAR-T Therapy JNJ-4528 Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of Relapsed or Refractory Multiple Myeloma

Newest designation for JNJ-4528 is supported by Phase 1b/2 CARTITUDE-1 study in adults with relapsed or refractory multiple myeloma Initial results from CARTITUDE-1 study to premiere at the American Society of Hematology Annual Meeting

Global health equity

December 8, 2019

Johnson & Johnson Announces Commitment to Support Republic of Rwanda’s Preparedness Against Ebola Outbreak

Up to 200,000 Regimens of Janssen’s Investigational Ebola Vaccine to be Supplied to Rwanda for Use in Border Region near Democratic Republic of the Congo (DRC)

Innovative Medicine

December 2, 2019

Johnson & Johnson Announces Winners of Champions of Science® Storytelling Challenge – Latin America and the Caribbean Edition

Program Spotlights Scientific Contributions and Personal Journeys of Scientists Across the Region

Search Results

No Results

Search Results

You are now leaving jnj.com/innovativemedicine